CG Oncology (NASDAQ:CGON - Get Free Report) had its price target raised by stock analysts at Guggenheim from $89.00 to $120.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has a "buy" rating on the stock. Guggenheim's price objective would suggest a potential upside of 46.28% from the stock's previous close.
A number of other equities analysts have also issued reports on the stock. Piper Sandler upped their target price on shares of CG Oncology from $82.00 to $85.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Morgan Stanley boosted their price objective on shares of CG Oncology from $102.00 to $117.00 and gave the stock an "overweight" rating in a research report on Wednesday. Wedbush raised their target price on shares of CG Oncology from $84.00 to $91.00 and gave the company an "outperform" rating in a research note on Tuesday. HC Wainwright raised their price target on CG Oncology from $100.00 to $115.00 and gave the stock a "buy" rating in a research report on Tuesday. Finally, Truist Financial reaffirmed a "buy" rating and issued a $100.00 target price (up from $85.00) on shares of CG Oncology in a research note on Tuesday. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, CG Oncology presently has an average rating of "Moderate Buy" and an average target price of $102.22.
View Our Latest Stock Analysis on CG Oncology
CG Oncology Price Performance
Shares of CGON opened at $82.04 on Thursday. The company has a market capitalization of $7.33 billion, a P/E ratio of -30.05 and a beta of 0.35. CG Oncology has a one year low of $37.01 and a one year high of $93.95. The business's 50 day simple moving average is $68.51 and its 200-day simple moving average is $66.96.
CG Oncology (NASDAQ:CGON - Get Free Report) last released its quarterly earnings results on Friday, November 6th. The company reported ($0.64) earnings per share for the quarter, beating analysts' consensus estimates of ($0.83) by $0.19. CG Oncology had a negative return on equity of 24.58% and a negative net margin of 3,851.09%. The firm had revenue of $1.60 million during the quarter, compared to analysts' expectations of $0.55 million. On average, sell-side analysts anticipate that CG Oncology will post -2.97 EPS for the current fiscal year.
Insider Activity
In other news, Director Leonard Post sold 1,000 shares of the stock in a transaction on Monday, November 16th. The stock was sold at an average price of $92.00, for a total transaction of $92,000.00. Following the sale, the director directly owned 1,000 shares of the company's stock, valued at approximately $92,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Arthur Kuan acquired 30,000 shares of the stock in a transaction on Wednesday, November 18th. The shares were purchased at an average price of $78.88 per share, with a total value of $2,366,400.00. Following the completion of the transaction, the chief executive officer owned 228,916 shares of the company's stock, valued at approximately $18,056,894.08. This represents a 15.08% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have sold 3,000 shares of company stock valued at $227,040. 4.80% of the stock is owned by insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. Fiduciary Financial Advisors bought a new stake in shares of CG Oncology in the 2nd quarter valued at $28,000. Manchester Capital Management LLC boosted its holdings in CG Oncology by 2,895.5% in the third quarter. Manchester Capital Management LLC now owns 659 shares of the company's stock worth $47,000 after acquiring an additional 637 shares in the last quarter. Covestor Ltd grew its position in CG Oncology by 72.6% in the 3rd quarter. Covestor Ltd now owns 770 shares of the company's stock valued at $55,000 after purchasing an additional 324 shares during the period. Fifth Third Bancorp acquired a new position in shares of CG Oncology during the first quarter valued at about $74,000. Finally, GAMMA Investing LLC boosted its position in shares of CG Oncology by 47.9% during the third quarter. GAMMA Investing LLC now owns 1,081 shares of the company's stock valued at $77,000 after buying an additional 350 shares during the last quarter. Institutional investors and hedge funds own 26.56% of the company's stock.
Recent CG Oncology Headlines
Here are a few of the latest headlines about CGON:
- Positive Sentiment: Analysts have also raised targets: Morgan Stanley lifted its target to $117 and Truist raised its target to $100, both with favorable ratings. The moves add to the positive analyst outlook, though targets are not guarantees of future returns. Truist analyst coverage
- Positive Sentiment: Recent attention has also focused on Phase 3 results for cretostimogene, which reportedly reduced bladder-cancer recurrence by 68%. The finding could support the therapy’s commercial prospects, subject to further data and regulatory review. Phase 3 results coverage
- Negative Sentiment: Director Leonard Post sold 1,000 shares for $92,000, cutting his direct holding by half. The sale is a modest counterpoint to the larger insider purchases. Director SEC filing
CG Oncology Company Profile
(
Get Free Report)
CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company's research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CG Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.
While CG Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.